Cardiac troponins T and I are considered highly sensitive and specific markers
for the diagnosis of acute myocardial infarction. Currently, a series of
nonprimary cardiac abnormalities may manifest as an elevation in high-sensitive
assays. The reduction in their detection limits has allowed earlier diagnosis
and the use of evidence-based therapeutic measures; however, this characteristic
has increased the spectrum of detectable noncoronary heart diseases, which poses
challenges for characterizing acute coronary syndromes and creates a new role
for these tests in known disorders in intensive care units, especially sepsis.
Management of patients through a greater understanding of how these markers
behave should be re-evaluated to ensure their correct interpretation.